Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Long-Term Deferred Tax (2021 - 2025)

Historic Long-Term Deferred Tax for Collegium Pharmaceutical (COLL) over the last 5 years, with Q3 2025 value amounting to $102.5 million.

  • Collegium Pharmaceutical's Long-Term Deferred Tax rose 4133.0% to $102.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.5 million, marking a year-over-year increase of 4133.0%. This contributed to the annual value of $98.0 million for FY2024, which is 27333.1% up from last year.
  • Collegium Pharmaceutical's Long-Term Deferred Tax amounted to $102.5 million in Q3 2025, which was up 4133.0% from $92.0 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Long-Term Deferred Tax ranged from a high of $102.5 million in Q3 2025 and a low of $24.0 million during Q4 2022
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $32.4 million (2024), whereas its average is $51.7 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 6931.14% in 2022, then surged by 27333.1% in 2024.
  • Collegium Pharmaceutical's Long-Term Deferred Tax (Quarter) stood at $78.0 million in 2021, then tumbled by 69.31% to $24.0 million in 2022, then rose by 9.64% to $26.3 million in 2023, then skyrocketed by 273.33% to $98.0 million in 2024, then increased by 4.53% to $102.5 million in 2025.
  • Its last three reported values are $102.5 million in Q3 2025, $92.0 million for Q2 2025, and $91.7 million during Q1 2025.